BTK

ENSG00000010671
Target class
Kinase
Chromosome
X
Approved drugs
8
Clinical candidates (approved and in development)
23

Approved drugs
8
ClinGen gene-disease validity
Definitive
Clinical candidates (approved and in development)
23

Chemical probe available
Yes

Target name
BTK
Gene name
Bruton tyrosine kinase
Gene symbol
BTK
Protein name
Tyrosine-protein kinase BTK (EC 2.7.10.2) (Agammaglobulinemia tyrosine kinase) (ATK) (B-cell progenitor kinase) (BPK) (Bruton tyrosine kinase)

  • ATK
  • XLA
  • PSCTK1

  • AGMX1
  • IMD1

Gene biotype
Protein coding
Gene family
Pleckstrin homology domain containing|SH2 domain containing|Tec family tyrosine kinases
Target class
Kinase
Target type
Human gene

Tissues expressed in
34
Protein localisation evidence grade
Supported
Highest tissue expression
114
Tissue specificity (Gini)
0.741
Tissue specificity (tau)
0.967

KEGG gene identifiers
  • hsa:695
Protein interaction confidence
0.8607
Protein interaction partners
70

  • R-HSA-1236974
  • R-HSA-166058
  • R-HSA-2029482
  • R-HSA-2424491
  • R-HSA-2871809
  • R-HSA-416476
  • R-HSA-416482
  • R-HSA-5602498
  • R-HSA-5603041
  • R-HSA-5663213
  • R-HSA-8964315
  • R-HSA-9664422
  • R-HSA-9679191
  • R-HSA-983695

End position
101390796
Start position
101349338
Chromosome
X
Strand
Reverse

Ensembl gene ID
ENSG00000010671
HGNC ID
HGNC:1133
www.genenames.org
NCBI Gene ID
695
UniProt ID
Q06187

  • Cytoplasm . Cell membrane
  • Peripheral membrane protein . Nucleus . Membrane raft . Note=In steady state, BTK is predominantly cytosolic. Following B-cell receptor (BCR) engagement by antigen, translocates to the plasma membrane through its PH domain. Plasma membrane localization is a critical step in the activation of BTK. A fraction of BTK also shuttles between the nucleus and the cytoplasm, and nuclear export is mediated by the nuclear export receptor CRM1. .
  • Cytosol
  • Plasma membrane

Tissue specificity (tau)
0.966665
Expression inequality (Gini)
0.741323

Expression in transcripts per million

Cells - EBV-transformed lymphocytes
114
Spleen
49.73
Whole Blood
28.49
Lung
17.43
Small Intestine - Terminal Ileum
9.89

Expression in transcripts per million

  • Cells - EBV-transformed lymphocytes114
  • Spleen49.73
  • Whole Blood28.49
  • Lung17.43
  • Small Intestine - Terminal Ileum9.89
  • Adipose - Subcutaneous6.07
  • Nerve - Tibial4.94
  • Brain - Spinal cord (cervical c-1)4.68
  • Adipose - Visceral (Omentum)4.67
  • Artery - Coronary4.08
  • Bladder3.94
  • Colon - Transverse3.66
  • Esophagus - Muscularis3.19
  • Artery - Aorta3.13
  • Esophagus - Gastroesophageal Junction3.08
  • Breast - Mammary Tissue2.95
  • Minor Salivary Gland2.93
  • Skin - Sun Exposed (Lower leg)2.85
  • Prostate2.56
  • Cervix - Endocervix2.55
  • Skin - Not Sun Exposed (Suprapubic)2.53
  • Colon - Sigmoid2.42
  • Uterus2.38
  • Vagina2.33
  • Stomach2.32

And 29 more, listed on the interactive page.

  • regulation of catalytic activity

    Studies

    • biochemical: NVS_ENZ_hBTK, is one of one assay component(s) measured or calculated from the NVS_ENZ_hBTK assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.

    Biological samples

    • cell-free
    Evidence source
    www.epa.gov

Related records

Trials (1,490)

Drugs (24)